First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE ...

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GIEnrollment continues in Phase 2b portion ...

The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs ...

Aqilion, a Swedish biopharma company developing therapies for diseases driven by chronic inflammation and dysregulated immune ...

Analyst Douglas Loe said the Victoria, B.C.-based biotechnology company’s proprietary drug-delivery platform positions it to ...